Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patent challenge
Pharma
FTC targets Novo's Ozempic among 300-plus 'junk' patents
Similar to its first round of challenge against allegedly improper listings in the FDA's Orange Book, the FTC is again targeting drug-device combos.
Angus Liu
May 1, 2024 7:30am
Merck challenges Johns Hopkins University's Keytruda patents
Mar 14, 2024 7:30am
GSK, Amneal and Kaleo walk back patents after FTC's challenge
Dec 21, 2023 11:08am
FDA endorses Avadel's Lumryz, a major threat to Jazz's Xyrem
May 2, 2023 8:00am
UCB's second shot at Neupro patent validation fails on appeal
Apr 13, 2023 11:51am
Court upholds prior strike of Arbutus patent in Moderna case
Apr 12, 2023 11:44am